← Watchlist
REGNT1

REGENERON PHARMACEUTICALS, INC.

EDGAR →Research This →

Financial Intelligence

Scored 6/28/2026

Buffett Quality

2.0/10

Lynch Category

Stalwart

Margin of Safety

—

Acquisition Risk

Not flagged

Owner Earnings

$5.0B

Recent Signals

20 found
insider_transaction

REGENERON PHARMACEUTICALS, INC.

is_buy: false · shares: 24 · filing_date: 2026-05-04

5/4/2026

50%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/12/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/12/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/12/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/12/2023

45%

Watch Reason

S&P 500 / major index component — seeded via EDGAR